Relay Therapeutics

Edit info

Founded: 2016

Location: Cambridge, MA

Employee range: 50 - 200

Clinical stage: Clin1b

Therapy area: Oncology

Drug types: ONC

Lead product: RLY-1971 (partner: Genentech)

Funding: $350M stock Oct 2021; $460M IPO Jul 2020; $400M Dec 2018; $63M Dec 2017; $57M A Sep 2016

Investors: Softbank

relaytx.com

linkedin.com

job board

Business:

Motion-based Drug Design

Drug notes:

RLY-4008 Clin1 multiple cancers; RLY-2608 Clin1 multiple cancers; 3 programs Clin0 oncology, undisclosed

About:

Relay Therapeutics is identifying drugs to alter protein kinetics to treat patients with cancer and genetic diseases. Proteins are not stationary - they move, and how they move can inform function and disease. Using their Dynamo platform, Relay is visualizing protein motions in HD movies and pioneering Motion-based Drug Design. The platform combines both deep structural understanding and chemical biology insights with AI and physics-based simulations to harness protein dynamics. With this, Relay can then develop unique hypotheses for how best to modulate a protein’s behavior and identify potential novel allosteric binding sites for therapeutics. Relay’s pipeline includes several promising product candidates in early and preclinical stages.